Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance

Publish date:: September 27, 2019

Key clinical point: Lenalidomide maintenance after chemoimmunotherapy prolongs progression- and event-free survival, but is associated with the potential risk for B-cell acute lymphoblastic leukemia (B-ALL).

Major finding: Three cases of ALL occurred in the lenalidomide maintenance arm.

Study details: 4-year follow-up of the phase 3 CLLM1 study of 89 patients.

Disclosures: The CLLM1 study was funded by Celgene.

Citation:

Furstenau M et al. iwCLL 2019, Abstract 2017.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,